Journal article

Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity

Curr.Opin.Investig.Drugs, vol. 7, issue 10 (2006) pp. 924-935

  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.
Sign in to save reference


Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed

Author-supplied keywords

  • Adverse effects
  • Anti-Obesity Agents
  • Clinical Trials,Phase I as Topic
  • Clinical Trials,Phase II as Topic
  • Diabetes Mellitus,Type 2
  • Hexoses
  • Humans
  • Hypoglycemic Agents
  • Structure-Activity Relationship
  • animals
  • contraindications
  • drug therapy
  • metabolism
  • obesity
  • pharmacokinetics
  • therapeutic use
  • toxicity

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • PMID: 17086938


  • M C Moore

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free